Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab + Bevacizumab + CAPOX for pMMR/MSS Colorectal Cancer Liver Metastases
NCT05588297Phase 2Unknown
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Oct 2022
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in colorectal cancer (CRC), sponsored by Shanghai Changzheng Hospital. Primary endpoints: R0 resection rate at 10 weeks, Pathological complete response rate at 15 weeks and 1 more. Status: unknown.
02
Drugs
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05588297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05588297.